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Available online 1 October 2016Peripheral blood was collected from a 1-year-old male patient with an X-linked recessive mutation of Iduronate
2-sulfatase (IDS) gene (NM_000202.7(IDS):c.85CNT) causingMPS II (OMIM309900). Peripheral bloodmononu-
clear cells (PBMCs) were reprogrammed by lentiviral delivery of a self-silencing hOKSMpolycistronic vector. The
pluripotency of the iPSC line was conﬁrmed by the expression of pluripotency-associated markers and in vitro
spontaneous differentiation towards the 3 germ layers. The iPSC line showed normal karyotype. The cell line of-
fers a good platform to study MPS II pathophysiology, for drug testing, early biomarker discovery and gene ther-
apy studies.. This is an op© 2016 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY license
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Peripheral blood was collected from a 1-year-old male patient with
genetically characterized MPS II disorder diagnosed by Department of
Pediatrics, University of Pécs (Hungary). Based on the clinical symptoms
of the patient, the disorder was determined to be severe MPS II. The pa-
tient carries a pathogenic, X-linked, hemizygous mutation of the IDS
gene (NM_000202.7(IDS):c.85CNT, p.Gln29Ter). The single nucleotide
variation (SNV) results a premature termination codon, leading to
Iduronate 2-sulfatase enzyme deﬁciency and to the severe accumula-
tion of glycosaminoglycans. Mutations of IDS gene have been shown
to cause MPS II disorder (Wraith et al. 2008). In the patient-derived
iPSCs the presence of the pathogenicmutationwas conﬁrmed by Sanger
sequencing of the PCR product harboring the SNV (Table 1, Fig. 1A).
To generate the MPSII-1.3 iPSC line the pRRL.PPT.SF.hOKSMco.
idTomato.preFRT lentiviral vector was used, which was shown that
under certain condition is self-silencing shortly after transduction
(Voelkel et al. 2010; Warlich et al. 2011). TRA-1-60 expressing iPSC-
like colonies were picked 18–21 days post-transduction, based on in
vivo immunocytochemistry staining (ICC) (Fig. 1B). Seven stable lines
were maintained and based on morphological criteria the MPSII-1.3
was chosen for further examination.
The pluripotency of MPSII-1.3 line was conﬁrmed by alkaline phos-
phatase staining (ALP) and by ICC for endogenous NANOG and E-
CADHERIN (Fig. 1B) after silencing of the exogenous hOKSM construct.the CC BY license (http://creativecommons.org/licenses/by/4.0/).
Table 1
Primers used in the study.
Gene
Symbol
Nucleotide
Change
Protein
Change
Fwd and Rvs primers (5′ -
3′)
PCR
product
(bp)
IDS c.85CNT
(NM_000202.7)
p.Gln29Ter TTCCCGACGAGGAGGTCTCT
ATGCAGGAAAGGACAGATGG
653
483E. Varga et al. / Stem Cell Research 17 (2016) 482–484The in vitro spontaneous differentiation potential of the iPSC line to-
wards the three germ layers was demonstrated by the expression of ec-
todermal (βIII-TUBULIN), mesodermal (BRACHYURY) and endodermal
(GATA4) markers (Fig. 1B) using ICC.
The karyotype of theMPSII-1.3 iPSC linewas determined by Giemsa-
banding, proving normal diploid 46, XY karyotype, without any detect-
able abnormalities (Fig. 1B).Materials and methods
Experimental procedures
The chemicals were purchased from Sigma-Aldrich and all the cul-
ture reagents from Thermo Fisher Scientiﬁc, unless otherwise speciﬁed.Cell culture
All cells were cultured at 37 °C in humidiﬁed atmosphere containing
5%CO2. The iPSCswere cultured onMatrigel (BDBiosciences) inmTeSR-Gene
Symbol
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IDS c.85C>T (NM_000202.7)
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Fig. 1.Characterization ofMPSII-1.3 iPSC line. A) Sanger sequencingof the region containing the
colonies based on in vivo TRA-1-60 ICC (4×), morphology of the generated iPSC (4×), the iPSC
associatedmarkers: NANOG(20×), E-CADHERIN (40×) (in green), nucleuswas labelledwithDA
for mesodermal (BRACHYURY), ectodermal (βIII-TUBULIN) and endodermal (GATA4) germ la
normal 46 chromosomes (XY).1 medium (Stem Cell Technologies) following the manufacturer's
instructions.
Reprogramming of PBMCs
PBMCs were isolated using the Vacutainer® CPT™ Cell Preparation
Tube with Sodium Heparin (BD Biosciences). PBMCs were seeded (1 ×
106 cells) in Expansion Medium (EM): QBSF-60 medium (Quality Bio-
logical) supplemented with 50 μg/ml Ascorbic acid, 1% Pen/Strep,
50 ng/ml SCF (R&D systems), 10 ng/ml IL-3 (R&D systems), 2 U/ml
EPO (R&D systems), 40 ng/ml IGF-1 (R&D systems) and 1 μM Dexa-
methasone. Three days later the cells were transduced with
pRRL.PPT.SF.hOKSMco.idTomato.preFRT (Voelkel et al. 2010; Warlich
et al. 2011) vector using conventional lentivirus transduction procedure
at 0,2–0,4MOI. Three days post-transduction the cellswere seeded onto
Mitomycin C treated-MEF in IMDMMEF medium (IMDM, 10% FBS, 1%
100× MEM Non-Essential Amino Acid Solution, 0.1 mM β-
mercaptoethanol, 1% Pen/Strep) supplemented with 50 μg/ml Ascorbic
acid and growth factors applied in EM medium. From day seven post-
transduction cells were cultured in HESC medium: DMEM/F12, 20%
Knockout Serum Replacement, 1% 100× MEM Non-Essential Amino
Acid Solution, 0.1 mM β-mercaptoethanol, 0.5% Pen/Strep, 10 ng/ml
bFGF, supplemented with 50 μg/ml Ascorbic acid. The appeared ES-
like colonies were manually picked (Day 18–21) and cultured as iPSCs
thereafter.
Alkaline phosphatase staining
Following 4% PFA ﬁxation the cells were incubatedwith ALP solution
for 30 min at RT. The stained cells were observed under invertedReverse
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NM_000202.7(IDS):c.85CNT SNV in thenewly established iPSC line. B) Top: Pickingof iPSC
line showed Alkaline Phosphatase activity (ALP) (10×) and was positive for pluripotency-
PI (in blue). Bottom: Spontaneous differentiation potential (Day 14)was conﬁrmedby ICC
yers (40×) (in green), the nucleus was labelled with DAPI (in blue), karyogram showing
Table 2
Antibodies used in this study.
Manufacturer Dilution
Pluripotency markers
Mouse anti-Tra-1-60, IgM Santa Cruz 1/50
Mouse anti-E-Cadherin (human) Thermo Fischer Sci. 1/1000
Goat anti-hNanog R&D Systems 1/50
Three germ layer markers
Rabbit anti-βIII-Tubulin Covance 1/2000
Rabbit anti-BrachyuryT Santa Cruz 1/50
Mouse anti-GATA4 Santa Cruz 1/50
Secondary Antibodies
Alexa Fluor 488 Donkey Anti-Mouse IgM Jackson ImmunoResearch 1/100
Alexa Fluor 488 donkey anti-goat IgG Thermo Fischer Sci. 1/2000
Alexa Fluor 488 donkey anti-mouse IgG Thermo Fischer Sci. 1/2000
Alexa Fluor 488 donkey anti-rabbit IgG Thermo Fischer Sci. 1/2000
484 E. Varga et al. / Stem Cell Research 17 (2016) 482–484microscope. The ALP solution consisted of 29.7mMTRIS base and 6mM
maleic acid (Fluka) pH 8.5–9.0; supplemented with 0.08% MgCl2,
10.8 mM Naphtol-As MX Phosphate and 23 μM Fast Red TR Salt.Immunocytochemistry staining
The expression of speciﬁc pluripotency and germ layer markers
were analyzed using conventional ICC staining. The cells were stained
in vivo or ﬁxed in 4% PFA. The antibodies and applied dilutions are listed
in Table 2. The cells were observed under ﬂuorescent microscope
equippedwith 3D imagingmodule (AxioImager systemwith ApoTome,
Carl Zeiss) controlled by AxioVision 4.8.1 Microscope software (Carl
Zeiss).Karyotyping
Cells were treated with Demecolcine solution (10 μg/ml in HBSS),
and processed with standard methods. Giemsa-banded karyotype was
performed and a minimum of 20 metaphases were analyzed. The chro-
mosomes were classiﬁed according to the International System for
Human Cytogenetic Nomenclature (ISCN).Sanger sequencing
To conﬁrm the presence of the pathogenic IDSmutation in the newly
established iPSC line PCR primers were designed to the region of inter-
est (Table 1). PCR reactions were performed using Phusion Hot Start II
High-Fidelity DNA Polymerase and MPSII-1.3 gDNA as the template.
The PCR product was puriﬁed with GenElute PCR cleanup kit and se-
quenced directly using an ABI Prism 3130xl Genetic Analyzer (Applied
Biosystems) and BigDye Terminator Cycle Sequencing v3.1 Kit (Applied
Biosystems).
In vitro spontaneous differentiation
Cell clumps were cultured in suspension for ﬁve days in mTeSR-1.
The formed EBswere plated on 0.1% gelatin covered cover slips in differ-
entiation medium: DMEM, 20% FBS, 1% 100× MEM Non-Essential
Amino Acid Solution, 0.1 mM β-mercaptoethanol, 1% Pen/Strep. The
cells were ﬁxed on Day 14 of differentiation with 4% PFA and stained
for the 3 germ layer markers (Table 2).
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